CUSIP No. 05454B105
ITEM 1. | SECURITY AND ISSUER |
This Amendment No. 2 (this “Amendment”) amends and supplements the Schedule 13D (the “Schedule 13D”) filed by the Reporting Persons (as defined below) on May 23, 2019, as amended, with respect to the common stock, $0.001 par value per share (“Common Stock”), of Axcella Health Inc. (the “Issuer” or the “Company”). Except as specifically provided herein, this Amendment does not modify any of the information previously reported in the Schedule 13D.
ITEM 4. | PURPOSE OF TRANSACTION |
Item 4 is hereby amended to include the following:
On March 16, 2022, pursuant to a Securities Purchase Agreement by and among the Issuer and the purchasers named therein (the “Purchase Agreement”), Flagship Ventures Fund IV, L.P. (“Flagship Fund IV”), Flagship Ventures Fund IV-Rx, L.P. (“Flagship Fund IV-Rx”) and Flagship Ventures Opportunities Fund I, L.P. (“Flagship Opportunities I”) purchased an additional 3,791,623 shares, 947,905 shares and 1,579,843 shares, respectively, of the Issuer’s Common Stock in a registered direct offering (the “March 2022 Offering”) at the price per share of $1.91.
ITEM 5. | INTEREST IN SECURITIES OF THE ISSUER |
Item 5(a)-(c) is hereby amended and restated as follows:
(a)-(b) The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 51,777,957 outstanding shares of Common Stock immediately following the March 2022 Offering, as reported in the Issuer’s prospectus supplement on Form 424(b)(5) filed with the Securities and Exchange Commission on March 16, 2022.
Flagship VentureLabs IV, LLC (“VentureLabs IV” and together with Flagship Fund IV and Flagship Fund IV-Rx, the “Flagship IV Funds”), Flagship Fund IV and Flagship Fund IV-Rx directly hold 2,035,830 shares, 8,600,403 shares and 2,004,657 shares of Common Stock, respectively. Flagship Fund IV, as the manager of VentureLabs IV, may be deemed to beneficially own the shares directly held by VentureLabs IV. Flagship Ventures Fund IV General Partner LLC (“Flagship Fund IV GP”), as the general partner of the Flagship Fund IV Funds, may be deemed to beneficially own the shares directly held by the Flagship Fund IV Funds.
Flagship Ventures Fund 2007, L.P. (“Flagship Fund 2007”) directly holds 1,761,029 shares of Common Stock. Flagship Ventures 2007 General Partner LLC (“Flagship 2007 GP”), as the general partner of Flagship Fund 2007, may be deemed to beneficially own the shares directly held by Flagship Fund 2007.
Flagship Opportunities I directly holds 4,465,866 shares of Common Stock. Flagship Ventures Opportunities Fund I General Partner LLC (“Flagship Opportunities GP”), as the general partner of Flagship Opportunities I, may be deemed to beneficially own the shares directly held by Flagship Opportunities I.
Noubar B. Afeyan, Ph.D., as the sole manager of Flagship Fund IV GP, Flagship Fund 2007 GP and Flagship Opportunities GP, may be deemed to beneficially own the shares directly held by the Flagship IV Funds, Flagship Fund 2007 and Flagship Opportunities I.
(c) On March 16, 2022, Flagship Fund IV, Flagship Fund IV-Rx and Flagship Opportunities I purchased an additional 3,791,623 shares, 947,905 shares and 1,579,843 shares, respectively, of the Issuer’s Common Stock in connection with the Issuer’s March 2022 Offering. The purchase price was $1.91 per share.